文献速递药物相互作用肝肾功能剂量调整特殊人群用药

三种已获批JAK抑制剂治疗类风湿关节炎的药代动力学药物相互作用潜力批判性评估

Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
PubMed 文献 · Drug Saf · 2020-01-01

本文批判性评估托法替布、巴瑞替尼和乌帕替尼的药物相互作用潜力,为类风湿关节炎患者根据合并用药及肾/肝损伤状态选择最适JAK抑制剂提供平衡视角。基于评估,三种药物总体利于联合处方;CYP3A4抑制或诱导改变托法替布和乌帕替尼暴露但不影响巴瑞替尼,转运体抑制改变巴瑞替尼处置;肾损伤进展时托法替布和巴瑞替尼需调整剂量而乌帕替尼不需,中度肝损伤仅托法替布需调整剂量。

要点

  • CYP3A4抑制或诱导改变托法替布和乌帕替尼暴露,但不影响巴瑞替尼暴露。
  • 转运体抑制改变巴瑞替尼处置,对托法替布或乌帕替尼影响不同。
  • 肾损伤轻至重度进展时托法替布和巴瑞替尼需调整剂量,乌帕替尼不需。

核心结论

  • 三种JAK抑制剂总体处置良好且无 perpetrator 活性,但作为 victim 药物存在细微药代动力学差异,多药合用时需考虑。

研究设计与样本

  • 本文为批判性评估综述,纳入托法替布、巴瑞替尼和乌帕替尼三种已获批JAK抑制剂的药物相互作用潜力分析,未报告检索范围与样本量。

主要发现

  • CYP3A4相关抑制或诱导改变托法替布和乌帕替尼的AUC,但不影响巴瑞替尼暴露。
  • 转运体药物相互作用研究显示,巴瑞替尼处置被某些转运体抑制剂改变,与托法替布或乌帕替尼不同。
  • 肾损伤从轻度进展至重度时,托法替布或巴瑞替尼需调整剂量,乌帕替尼不需。
  • 中度肝损伤患者托法替布需调整剂量,巴瑞替尼或乌帕替尼不需。

临床怎么用

  • 合并CYP3A4抑制剂或诱导剂时优先考虑巴瑞替尼以避免暴露改变。
  • 合并转运体抑制剂时需关注巴瑞替尼处置变化。
  • 根据肾损伤程度调整托法替布或巴瑞替尼剂量,乌帕替尼无需调整。
  • 中度肝损伤患者使用托法替布需调整剂量,巴瑞替尼或乌帕替尼无需调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of novel, small-molecule Janus kinase inhibitors namely tofacitinib, baricitinib and upadacitinib has provided an alternative treatment option for patients with rheumatoid arthritis outside of traditional drugs and expensive biologics. This review aimed to critically assess the drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib and provide a balanced perspective for choosing the most appropriate Janus kinase inhibitor based on the needs of patients with rheumatoid arthritis including co-medications and renal/hepatic impairment status. Based on the critical assessment, all three approved Janus kinase inhibitors generally provide a favourable opportunity for co-prescription with a plethora of drugs. While cytochrome P450 3A4-related inhibition or induction altered the exposures (area under the curve) of tofacitinib and upadacitinib, it did not impact the exposure of baricitinib. Transporter drug-drug interaction studies revealed that the disposition of baricitinib was altered with certain transporter inhibitors as compared with either tofacitinib or upadacitinib. Adjustment of tofacitinib or baricitinib dosages but not that of upadacitinib is required with the progression of renal impairment from a mild to a severe condition. While the dosage of tofacitinib needs to be adjusted for patients with moderate hepatic impairment status, it is not the case for either baricitinib or upadacitinib. Assessment of the drug-drug interaction potential suggests that tofacitinib, baricitinib and upadacitinib generally show a favourable disposition with no perpetrator activity; however, as victim drugs, they show subtle pharmacokinetic differences that may be considered during polypharmacy. Moreover, careful choice of the three drugs could be made in patients with rheumatoid arthritis with varying degrees of renal/hepatic impairments.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Veeravalli V, Dash RP, Thomas JA, et al. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Saf. 2020. PMID: 32367507. doi:10.1007/s40264-020-00938-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。